Results 271 to 280 of about 564,426 (377)

Cyclin D3 Expression in Non-Hodgkin Lymphoma [PDF]

, 2001
Michael Møller, Ole Nielsen, Niels T. Pedersen   +2 more
openalex   +1 more source

Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

European Journal of Haematology, EarlyView.
ABSTRACT Chimeric antigen receptor T‐cell therapy (CART) has replaced salvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation (HDT‐ASCT) as the preferred second‐line treatment for early relapsed (< 12 months) large B‐cell lymphoma (LBCL).
Hilde T. van der Galiën, Hilde A. M. Kooistra, Robby Kibbelaar, Nic J. G. M. Veeger, Marcel Nijland, Gerwin Huls, Tom van Meerten, Rozemarijn S. van Rijn, on behalf of The Hemobase Population Registry Consortium, Gerrit Jan Veldhuis, Gerhard Woolthuis, Leonie van der Burg, Bas van Rees, Mels Hoogendoorn, Bas Franken, Esther de Waal, Rozemarijn van Rijn, Peter Joosten, Hilde van der Galiën, Eric van Roon, Sjoerd Hovenga, Frank Schipper, Harmen van Kamp, Adrian Kruit, Huib Storm, Harry de Wit, Willeke Ferket‐Franken, Wilma Smit, Renske Vlasman, Robby Kibbelaar, Roy Jurhill, Sophie Dijkhuizen, Elise van der Logt, Melvin Kilsdonk   +33 more
wiley   +1 more source

Predicting risk in Hodgkin lymphoma for research and clinical practice. [PDF]

Blood Adv
Chen R, Gordon LI.
europepmc   +1 more source

Trends in non-hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States [PDF]

, 2001
W. Craig Hooper, Robert C. Holman, Matthew Clarke, Terence L. Chorba   +3 more
openalex   +1 more source

Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine

European Journal of Haematology, EarlyView.
ABSTRACT JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers.
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, Jürgen Wehmeyer, Eyck von der Heyde, Hans Tesch, Benedikt Gröschl, Petra Bachhuber, Susanne Großer, Michael Koehler, Heike L. Pahl   +15 more
wiley   +1 more source

Aberrant Expression and Oncogenic Activity of SPP1 in Hodgkin Lymphoma. [PDF]

Biomedicines
Nagel S, Meyer C.
europepmc   +1 more source

Evaluation of topotecan and etoposide for non-hodgkin lymphoma [PDF]

, 2001
Ramamohana R. Kancherla, Jayasree S. Nair, Tauseef Ahmed, Haroon Durrani, Karen Seiter, Anney Mannancheril, Yuk‐Ching Tse‐Dinh   +6 more
openalex   +1 more source

Physical and functional interactions between LDLR family members and CXCR4 in breast cancer

The FEBS Journal, EarlyView.
Here, we demonstrate that members of the low‐density lipoprotein receptor (LDLR) family can regulate C‐X‐C chemokine receptor type 4 (CXCR4) signaling and therefore affect CXCR4‐induced breast cancer metastasis. We found that very low‐density lipoprotein receptor (VLDLR), low‐density lipoprotein receptor‐related protein 8 (LRP8) and apolipoprotein E ...
Jiankang Zhang, Jinxiao Chen, Da Wo, En Ma, Hongwei Yan, Jun Peng, Dan‐ni Ren, Weidong Zhu   +7 more
wiley   +1 more source

Laryngeal non-Hodgkin lymphoma presenting as throat foreign body sensation: A case report. [PDF]

Medicine (Baltimore)
Liao H, He A, Yan F, He B.
europepmc   +1 more source

Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study

Cancer Epidemiology, Biomarkers and Prevention, 2016
T. Keegan, Mindy C Derouen, H. Parsons, C. Clarke, Debbie E. Goldberg, C. Flowers, S. Glaser   +6 more
semanticscholar   +1 more source